anemias due to disorders of glutathione metabolism Frontiers Study of Changes in Glutathione

Its always a moving target, right

To achieve this, there can be only two possibilities: (i) tumor cells may exhibit mechanism(s) removing malonyl-CoA but without directing it toward the fatty acyl synthase machinery, thus relieving carnitine palmitoyltransferase 1 inhibition, and/or (ii) cancers harbor a carnitine palmitoyltransferase 1 that is not sensitive to inhibition by malonyl-CoA

Injectable GHK-Cu Protocols For those considering injectable GHK-Cu, protocols are often tailored to specific therapeutic goals: GHK-Cu is typically cycled to prevent desensitization and minimize long-term side effects

These important interactions are beyond the scope of this initial investigation, but will be incorporated in future studies